Person: SÜMBÜL ŞEKERCİ, BETÜL
Loading...
Status
Organizational Units
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only Diyabet ve Prediyabet Hastalarındaki Kognitif Bozulmanın Hipertrigliseridemi İle İlişkisi(2023-06-14) Şekerci A.; Sümbül Şekerci B.; ŞEKERCİ, ABDÜSSELAM; SÜMBÜL ŞEKERCİ, BETÜLPublication Metadata only Treatment adherence and related factors in Parkinson's disease patients without dementia(2022-12-01) Sümbül Şekerci B.; Hanağası H. A.; Bilgiç B.; Emre M.; SÜMBÜL ŞEKERCİ, BETÜLBackground and Objective: Patients with Parkinson’s Disease (PD) have many risk factors for treatment nonadherence, such as cognitive impairment, depression, polypharmacy, and medication regimen complexity. Adherence in PD should be carefully monitored to accurately assess the patient’s clinical and treatment responseMethod: This is a cross-sectional observational study. Sixty patients who were diagnosed with PD according to the UK PD Association’s Brain Bank criteria and had at least primary school education participated in our study. Patients with a diagnosis of dementia or who received deep brain stimulation, apomorphine infusion, and levodopa/carbidopa intestinal gel therapy were excluded from the study. Main outcome measures: Adherence was evaluated with the 4-item Morisky medication adherence scale. The course of the patients was gauged with the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). MDS-UPDRS subscores are as follows; Part 1: nonmotor experiences of daily life Part 2: motor experiences of daily life Part 3: motor examination Part 4: motor complications. In the evaluation of patients, Schwab and England Activities of Daily Living Rating Scale (SE-ADL) was used for activities of daily living, MoCA for cognitive status, Beck Depression and anxiety scales for mood. The number of drugs used by the patients and LDED were calculated. Results: The mean age of the patients was 62.40 (± 10.25) and 70% of them were male (n:42). There was no significant difference between the adherence of the patients according to the Hoehn and Yahr stages. There was a significant correlation between adherence and depression (p 0.005, r - 0.372), anxiety (0.009 r - 0.357), UPDRS-1 (p 0.006 r - 0.373), UPDRS-2 (p 0.027 r - 0.304), SEADL (p 0.001, r 0.438) scores. When these variables were included in the regression analysis with the enter method, SE-ADL score were found to be significant for predicting adherence (p 0.041, OR 0.328). Conclusion: Motor and non-motor problems of daily life are associated with non-adherence in PD patients without dementia. Treatment of non-motor symptoms such as depression and anxiety may contribute to adherence. Higher independence of patients in daily life increases adherence.Publication Open Access Anticholinergic Burden, Polypharmacy, and Cognition in Parkinson's Disease Patients with Mild Cognitive Impairment: A Cross-Sectional Observational Study.(2022-10-21T00:00:00Z) Sumbul-Sekerci, Betül; Bilgic, Basar; Pasin, Ozge; Emre, Murat; Hanagasi, Hasmet A; SÜMBÜL ŞEKERCİ, BETÜL; PASİN, ÖZGEIntroduction: Anticholinergic burden may be an important risk factor for the cognitive impairment. Especially in polypharmacy, even drugs with low anticholinergic effects may contribute to a significant anticholinergic burden. The drugs with anticholinergic effects are used in treatment of motor and nonmotor symptoms of Parkinson’s disease (PD). Therefore, it is important to screen for polypharmacy and anticholinergic burden in PD patients with mild cognitive impairment (MCI). Methods: This cross-sectional study was conducted with 58 patients with PD. PD-MCI was diagnosed according to MDS Level 2 Comprehensive Assessment. Cognitive performance (attention – working memory, executive functions, language, memory, and visuospatial functions) of patients was evaluated. The anticholinergic burden was scored by Anticholinergic Cognitive Burden (ACB) Scale, Anticholinergic Risk Scale (ARS), and Anticholinergic Drug Scale (ADS). Results: There was no significant difference in anticholinergic burden between PD-MCI and PD-normal cognition. A significant concordance was observed between ACB, ARS, and ADS scores (p < 0.001; Kendall’s W = 0.653). While the variable predicting anticholinergic burden was the total number of drugs for ACB and ADS scales, it was the number of antiparkinson drugs for ARS scale. Conclusion: Patients with PD are at high risk for polypharmacy and anticholinergic burden. Anticholinergic burden should be considered in the selection of drugs, especially for comorbidities in patients with PD. No significant correlation was found between the cognition and anticholinergic burden in patients with PD-MCI. Although the risk scores of antiparkinson and other drugs were different among the 3 scales, significant concordance was observed between scales.Publication Metadata only Diyabet Hastalarında Gözardı Edilen Bir Komplikasyon: Kognitif Bozulma.(2022-12-23) Şekerci A.; Sümbül Şekerci B.; Selvitop R.; Yüksel Salduz Z. İ.; ŞEKERCİ, ABDÜSSELAM; SÜMBÜL ŞEKERCİ, BETÜL; YÜKSEL SALDUZ, ZEYNEB İREMPublication Metadata only Cognition And Anticholinergic Burden In Type 2 Diabetes Mellitus(2022-12-03) Şekerci A.; Sümbül Şekerci B.; Selvitop R.; Yüksel Salduz Z. İ.; ŞEKERCİ, ABDÜSSELAM; SÜMBÜL ŞEKERCİ, BETÜL; YÜKSEL SALDUZ, ZEYNEB İREMBackground and Objective: Cognitive impairment is one of the most important complications of type 2 diabetes mellitus (T2DM). Anticholinergic burden can cause cognitive decline. The aim of this study is to investigate the relationship between cognitive impairment and anticholinergic burden in patients with T2DM. Method: Seventy-three patients diagnosed with T2DM according to ADA criteria and using oral antidiabetic drugs for treatment participated in our study. Patients with a history of serious psychiatric (e.g.,major depressive disorder) or neurological disease (e.g., cerebrovascular disease, brain tumor, head trauma) were excluded. Main outcome measures: The cognition of the patients was evaluated with the Montreal Cognitive Assessment (MoCA). The cut-off score of the MoCA for cognitive impairment is 21 according to the validation of the Turkish Version. The drugs used by the patients were analyzed and the anticholinergic burden was calculated according to the anticholinergic cognitive burden (ACB) scale. Results: The mean age of the patients in our study was 50.60 (± 8.19). While ACB was not observed in the drugs of 67 patients, 5 patients used drugs with ACB Score of 1. The cognition of 45 (61.6%) patients with T2DM was impaired and 28 (38.3%) patients were normal. There is no significant difference in age of cognition groups. Attention (p \0.001), language (p \0.001) and orientation (p\ 0.001) scores were significantly worse in T2DM with impaired cognition. No significant difference was found between the ACB burden of DM patients with normal cognition and impaired cognition. Conclusion: In our study, no relationship was found between cognitive impairment in T2DM and ACB. Future studies involving larger sample and higher ACB may provide more detailed information.Publication Metadata only Non-medical Use of Prescription Psychostimulants and Academic Performance in Medical Students(2023-12-01) Sümbül Şekerci B.; Bektay M. Y.; Bildik Ö.; SÜMBÜL ŞEKERCİ, BETÜL; BİLDİK, ÖZLEMPublication Metadata only Effect of COVID-19 on Emergency Admissions for Young Patients with Ischemic Stroke: An Interrupted Time Series Analysis(2024-01-01) Sümbül Şekerci B.; Pasin Ö.; Yaman Kula A.; Pasin T.; Şekerci A.; SÜMBÜL ŞEKERCİ, BETÜL; PASİN, ÖZGE; YAMAN KULA, ASLI; ŞEKERCİ, ABDÜSSELAM